Spectrum of ocular toxicities from epidermal growth factor receptor inhibitors and their intermediate-term follow-up: A five-year review

Supportive Care in Cancer

Volumn 21, Issue 4, 2013, Pages 1167-1174

  Borkar, Durga S ^a   Lacouture, Mario E ^a,b   Basti, Surendra ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Drug induced blepharitis; Ocular toxicities of EGFR inhibitors; Trichomegaly

Indexed keywords

ANTIINFLAMMATORY AGENT; CETUXIMAB; DEXAMETHASONE PLUS NEOMYCIN PLUS POLYMYXIN B; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; EYE DROPS; FLUOROMETHOLONE; GEFITINIB; PANITUMUMAB; PIMECROLIMUS; TACROLIMUS;

ARTICLE; BEDTIME DOSAGE; BLEPHARITIS; BLURRED VISION; CHALAZION; COLORECTAL CANCER; COMPRESSION THERAPY; CONJUNCTIVITIS; CONTROLLED STUDY; CORNEA DISEASE; CORNEAL ABRASION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; DRY EYE; DYSFUNCTIONAL TEAR SYNDROME; ECTROPION; ENTROPION; EPIPHORA; EYE BURNING; EYE DISEASE; EYE REDNESS; EYE TOXICITY; EYELID DISEASE; FACE RASH; FEMALE; HUMAN; HYGIENE; HYPEREMIA; INTRAOCULAR FOREIGN BODY; LID HYGIENE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; OCULAR PRURITUS; OUTCOME ASSESSMENT; PHOTOPHOBIA; PRIORITY JOURNAL; SOLID TUMOR; TREATMENT DURATION; TRICHIASIS; TRICHOMEGALY;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; CHICAGO; EYE DISEASES; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MEDICAL AUDIT; NEOPLASMS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES;

EID: 84879799977     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-012-1645-y     Document Type: Article

References (40)

1. Reck M, van Zandwijk N, Gridelli C et al (2010) Erlotinib in advanced non-small cell lung cancer: efficacy and safety findings of the global phase IV tarceva lung cancer survival treatment study. J Thorac Oncol 5:1616-1622
2. Shepherd FA, Rodrigues Pereira J, Ciuleanu T et al (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353:123-132
3. Moore MJ, Goldstein D, Hamm J et al (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the national cancer institute of canada clinical trials group. J Clin Oncol 25:1960-1966
4. Cunningham D, Humblet Y, Siena S et al (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:337-345
5. Peeters M, Price TJ, Cervantes A et al (2010) Randomized phase iii study of panitumumab with fluorouracil, leucovorin, and irinotecan (folfiri) compared with folfiri alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol 28:4706-4713
6. Van Cutsem E, Peeters M, Siena S et al (2007) Open-label phase iii trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 25:1658-1664
7. Milton DT, Azzoli CG, Heelan RT et al (2006) A phase I/II study of weekly high-dose erlotinib in previously treated patients with nonsmall cell lung cancer. Cancer 107:1034-1041
8. Mok TS, Wu YL, Thongprasert S et al (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361:947-957
9. Yamaguchi K, Mochizuki M, Watanabe T et al (1994) Human T lymphotropic virus type 1 uveitis after Graves' disease. Br J Ophthalmol 78:163-166
10. Geyer CE, Forster J, Lindquist D et al (2006) Lapatinib plus capecitabine for her2-positive advanced breast cancer. N Engl J Med 355:2733-2743
11. Saltz LB, Meropol NJ, Loehrer PJ Sr et al (2004) Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 22:1201-1208
12. Baselga J, Rischin D, Ranson M et al (2002) Phase I safety, pharmacokinetic, and pharmacodynamic trial of zd1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol 20:4292-4302
13. Ranson M, Hammond LA, Ferry D et al (2002) Zd1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. J Clin Oncol 20:2240-2250
14. Perez-Soler R, Chachoua A, Hammond LA et al (2004) Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol 22:3238-3247
15. Soulieres D, Senzer NN, Vokes EE et al (2004) Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol 22:77-85
16. Fraunfelder FT, Fraunfelder FW (2012) Trichomegaly and other external eye side effects associated with epidermal growth factor. Cutan Ocul Toxicol 31:195-197
17. Lacouture ME, Basti S, Patel J et al (2006) The series clinic: an interdisciplinary approach to the management of toxicities of EGFR inhibitors. J Support Oncol 4:236-238
18. Behrens A, Doyle JJ, Stern L et al (2006) Dysfunctional tear syndrome: a Delphi approach to treatment recommendations. Cornea 25:900-907
19. Yano S, Kondo K, Yamaguchi M et al (2003) Distribution and function of egfr in human tissue and the effect of EGFR tyrosine kinase inhibition. Anticancer Res 23:3639-3650
20. Liu Z, Carvajal M, Carraway CA et al (2001) Expression of the receptor tyrosine kinases, epidermal growth factor receptor, erbb2, and erbb3, in human ocular surface epithelia. Cornea 20:81-85
21. Zieske JD, Wasson M (1993) Regional variation in distribution of EGF receptor in developing and adult corneal epithelium. J Cell Sci 106(Pt 1):145-152
22. Lane K, Goldstein SM (2007) Erlotinib-associated trichomegaly. Ophthal Plast Reconstr Surg 23:65-66
23. Pascual JC, Banuls J, Belinchon I et al (2004) Trichomegaly following treatment with gefitinib (zd1839). Br J Dermatol 151:1111-1112
24. Bouche O, Brixi-Benmansour H, Bertin A et al (2005) Trichomegaly of the eyelashes following treatment with cetuximab. Ann Oncol 16:1711-1712
25. Zhang G, Basti S, Jampol LM (2007) Acquired trichomegaly and symptomatic external ocular changes in patients receiving epidermal growth factor receptor inhibitors: case reports and a review of literature. Cornea 26:858-860
26. Melichar B, Nemcova I (2007) Eye complications of cetuximab therapy. Eur J Cancer Care (Engl) 16:439-443
27. Vaccaro M, Pollicino A, Barbuzza O et al (2009) Trichomegaly of the eyelashes following treatment with cetuximab. Clin Exp Dermatol 34:402-403
28. Johnson KS, Levin F, Chu DS (2009) Persistent corneal epithelial defect associated with erlotinib treatment. Cornea 28:706-707
29. Tonini G, Vincenzi B, Santini D et al (2005) Ocular toxicity related to cetuximab monotherapy in an advanced colorectal cancer patient. J Natl Cancer Inst 97:606-607
30. Dranko S, Kinney C, Ramanathan RK (2006) Ocular toxicity related to cetuximab monotherapy in patients with colorectal cancer. Clin Colorectal Cancer 6:224-225
31. Ramirez-Soria MP, Espana-Gregori E, Avino-Martinez J (2008) et al [Blepharitis related to cetuximab treatment in an advanced colorectal cancer patient]. Arch Soc Esp Oftalmologia 83:665-668
32. Frankfort BJ, Garibaldi DC (2007) Periocular cutaneous toxicity and cicatricial ectropion: a potential class effect of antineoplastic agents that inhibit egfr signaling. Ophthal Plast Reconstr Surg 23:496-497
33. Garibaldi DC, Adler RA (2007) Cicatricial ectropion associated with treatment of metastatic colorectal cancer with cetuximab. Ophthal Plast Reconstr Surg 23:62-63
34. Methvin AB, Gausas RE (2007) Newly recognized ocular side effects of erlotinib. Ophthal Plast Reconstr Surg 23:63-65
35. Burtness B, Anadkat M, Basti S et al (2009) NCCN task force report: management of dermatologic and other toxicities associated with EGFR inhibition in patients with cancer. J Natl Compr Canc Netw 7(Suppl 1):S5-S21, quiz S22-24
36. Basti S (2007) Ocular toxicities of epidermal growth factor receptor inhibitors and their management. Cancer Nurs 30:S10-S16
37. Foerster CG, Cursiefen C, Kruse FE (2008) Persisting corneal erosion under cetuximab (erbitux) treatment (epidermal growth factor receptor antibody). Cornea 27:612-614
38. Herbst RS, Prager D, Hermann R et al (2005) Tribute: a phase III trial of erlotinib hydrochloride (osi-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 23:5892-5899
39. Gatzemeier U, Pluzanska A, Szczesna A et al (2007) Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J Clin Oncol 25:1545-1552
40. Zhou S, Ren S, Yan L et al (2009) Clinical efficacy of erlotinib in patients previously treated for advanced non-small cell lung cancer. Respirology 14:709-715